Durvalumab and Enfortumab Vedotin Combination Cuts Bladder Cancer Mortality by 42 Percent

A novel combination of targeted therapy and immunotherapy administered around the time of surgery has reduced the risk of death from muscle-invasive bladder cancer by 42 percent. The phase 3 VOLGA trial results, presented this weekend at the European Society for Medical Oncology congress in Madrid, mark a substantial shift in urologic oncology.[2][5]

The regimen pairs the immunotherapy drug durvalumab with enfortumab vedotin, an antibody-drug conjugate. Patients receiving this doublet before and after radical cystectomy saw their risk of disease recurrence or progression fall by 49 percent compared to those undergoing standard surgical care.[3][4]

Muscle-invasive bladder cancer, which penetrates the thick muscle deep in the bladder wall, is notoriously difficult to treat. An estimated 83,000 new cases of bladder cancer are diagnosed annually in the United States alone, with about 25 percent presenting as muscle-invasive at the time of discovery.[1][2]

Historically, standard care has relied on cisplatin-based chemotherapy followed by the complete removal of the bladder, a life-altering procedure known as a radical cystectomy. However, roughly half of all patients diagnosed with this aggressive malignancy are ineligible for cisplatin due to poor kidney function or hearing loss.[5]

Delivering a targeted payload

For these individuals, the primary option has been proceeding directly to surgery, which carries a high rate of subsequent relapse. The VOLGA trial sought to bridge this therapeutic gap by deploying a two-pronged biological attack designed to eradicate microscopic disease before the operation.[1][6]

Enfortumab vedotin acts as a guided biological missile in this regimen. It seeks out the Nectin-4 protein commonly found on the surface of bladder cancer cells, binding to the receptor to deliver a highly toxic chemotherapy payload directly inside the malignant tissue.[1][4]

Durvalumab, marketed as Imfinzi by AstraZeneca, complements this targeted strike by blocking the PD-L1 pathway. This mechanism effectively removes the biochemical brakes that tumors use to hide, allowing the patient's own T-cells to recognize and destroy the cancer cells that the conjugate has damaged.[4][6]

Researchers enrolled patients globally, assigning them to receive either the experimental perioperative combination or the standard surgical approach. The data published in The New England Journal of Medicine confirmed that the dual therapy provided a statistically significant and clinically meaningful extension of overall survival.[1][3]

Reshaping the surgical landscape

"This is a transformative moment for patients who have historically faced a very narrow set of options," said Dr. Thomas Powles, a lead investigator on the trial. "Seeing a 42 percent reduction in mortality in this setting tells us we are fundamentally changing the disease trajectory."[2][5]

The survival curves presented in the trial data began to separate early and continued to widen as the months progressed. This sustained benefit suggests that the neoadjuvant phase—treatment given before surgery—effectively shrinks the primary tumor and clears circulating cells before the bladder is removed.[1][2]

Continuing the immunotherapy after the operation appears to consolidate these initial therapeutic gains. By maintaining immune pressure on any residual microscopic disease, the adjuvant phase of the durvalumab regimen helps prevent the distant metastases that typically claim patients' lives in the years following a cystectomy.[3][5]

The safety profile of the combination remained consistent with the known side effects of the two individual drugs. While adverse events such as peripheral neuropathy and skin reactions were recorded, investigators noted that the toxicity was generally manageable for the majority of the trial participants.[1][4]

Expanding access to care

Crucially, the addition of the systemic therapy did not increase the rate of severe surgical complications. Ensuring that patients remain fit enough to endure a radical cystectomy is a primary concern for urologists when evaluating any new neoadjuvant treatment protocol prior to the operating room.[2][5]

The success of the VOLGA trial represents a major victory for AstraZeneca's expanding oncology portfolio. The pharmaceutical company has invested heavily in exploring how antibody-drug conjugates can be sequenced or combined with its established checkpoint inhibitors across a variety of aggressive solid tumors.[4][6]

Industry analysts at the Madrid conference highlighted the broader clinical implications of these findings. Proving that this combination works in the localized, perioperative setting opens the door to treating patients much earlier in their disease course, before the cancer has an opportunity to spread.[6]

For the clinical community, the immediate focus will shift to integrating these findings into global treatment guidelines. Because the trial specifically included patients who were ineligible for cisplatin chemotherapy, the durvalumab doublet directly addresses one of the largest unmet needs in modern urologic oncology.[2][3]

Looking toward regulatory approval

Regulatory submissions based on the VOLGA data are expected to follow shortly in multiple jurisdictions. If approved by the Food and Drug Administration and the European Medicines Agency, the regimen would become the new benchmark for perioperative care in muscle-invasive disease.[4][5]

Patient advocacy groups have welcomed the results, noting the severe psychological toll that high recurrence rates take on survivors. Knowing that a pre- and post-surgical treatment can cut the risk of the cancer returning by nearly half provides a substantial measure of reassurance.[2][5]

The financial cost of the dual-drug regimen will likely become a topic of discussion as it moves toward clinical practice. Both antibody-drug conjugates and immunotherapies carry high list prices, which could pose access challenges in certain healthcare systems despite the clear survival advantages.[6]

As the oncology community digests the ESMO 2026 presentations, the consensus points toward a new standard of care. The era of relying solely on surgery for cisplatin-ineligible muscle-invasive bladder cancer is ending, replaced by a biologically driven approach that significantly extends human life.[5][6]